Tiroid papiller karsinomu ile renal hücreli karsinom birlikteliği olan hastalarda braf mutasyonu
Küçük Resim Yok
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Trakya Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
B tipi Raf kinaz , tümör oluşumunu tetikleyen, sitoplazmik bir protein kinazdır. B-Raf mutasyonu papiller tiroid kanserinde %25~82.3 sıklıkta ortaya çıkmaktadır. Renal hücreli karsinom hastalarında görülen B-Raf mutasyonu ise oldukça nadirdir. Ancak nadir de olsa mutasyonu olan vakalarda hedefe yönelik ajan seçilmesinin sağkalımı arttırdığı gösterilmiştir. Literatürde renal hücreli karsinom ve papiller tiroid kanserinin birlikteliği bulunan hastalarda B-Raf geninin araştırıldığı çalışmaya rastlanmamaktadır. Biz de bu hasta grubunda B-Raf gen analizini değerlendirmeyi amaçladık. Trakya Üniversitesi Tıp Fakültesi Endokrinoloji bölümünde 2007-2023 yılları arasında tanı almış 10 papiller tiroid kanseri renal hücreli karsinom hastası çalışmaya dahil edildi. B-Raf immünohistokimyasal boyama yöntemi ile çalışıldı. Çalışmanın sonucunda papiller tiroid kanseri materyalinden B-Raf çalışılan hastaların %60'ında B-Raf pozitifliği saptandı. Kalan %40'ında ise B-Raf negatif saptandı. Renal hücreli karsinom materyalinden B-Raf çalışılan hastaların %10'unda B-Raf pozitifliği saptandı. Kalan %90'ında ise B-Raf negatif saptandı. B-Raf pozitifliği olan papiller tiroid kanseri vakaları negatif olanlara göre yaşça daha ileriydi. Ekstratiroidal yayılım B-Raf pozitifliği olan papiller tiroid kanseri hastalarında istatistiksel olarak daha ileri saptandı. 1 vaka takiplerde exitus oldu. Bu vakanın tiroid materyali B-raf pozitifti ve sağkalımı 63 ay ile en kısa olan vakaydı. Papiller tiroid kanseri ve renal hücreli kanser birlikteliğinde B-Raf mutasyonunun klinikopatolojik etkilerinin olabileceği düşünülmüş olup altta yatan kesin mekanizmayı doğrulamak ve araştırmak için daha fazla çalışmaya ihtiyaç olduğu düşünülmüştür.
Type B Raf kinase is a cytoplasmic protein kinase that induces tumorigenesis. B-Raf mutation occurs with a frequency of 25~82.3% in papillary thyroid cancer. B-Raf mutation seen in renal cell carcinoma patients is very rare. However, in rare cases with mutations, it has been shown that choosing a targeted agent increases survival. No study in the literature investigates the B-Raf gene in patients with concomitant renal cell carcinoma and papillary thyroid cancer. We aimed to evaluate B-Raf gene analysis in this patient group. The study included ten patients with papillary thyroid cancer and renal cell carcinoma diagnosed in Trakya University Faculty of Medicine Department of Endocrinology between 2007-2023. B-Raf was studied with the immunohistochemical staining method. As a result of the study, B-Raf positivity was detected in 60% of the patients who studied B-Raf from papillary thyroid cancer material. The remaining 40% were found to be B-Raf negative. B-Raf positivity was detected in 10% of the patients whose renal cell carcinoma material B-Raf was studied. The remaining 90% were found to be B-Raf negative. Papillary thyroid cancer cases with B-Raf positivity were more advanced than those with negative B-Raf positivity. The extrathyroidal extension was statistically more advanced in patients with papillary thyroid cancer with B-Raf positivity. 1 case died during follow-up. The thyroid material of this case was B-raf positive and the survival was the shortest with 63 months.
Type B Raf kinase is a cytoplasmic protein kinase that induces tumorigenesis. B-Raf mutation occurs with a frequency of 25~82.3% in papillary thyroid cancer. B-Raf mutation seen in renal cell carcinoma patients is very rare. However, in rare cases with mutations, it has been shown that choosing a targeted agent increases survival. No study in the literature investigates the B-Raf gene in patients with concomitant renal cell carcinoma and papillary thyroid cancer. We aimed to evaluate B-Raf gene analysis in this patient group. The study included ten patients with papillary thyroid cancer and renal cell carcinoma diagnosed in Trakya University Faculty of Medicine Department of Endocrinology between 2007-2023. B-Raf was studied with the immunohistochemical staining method. As a result of the study, B-Raf positivity was detected in 60% of the patients who studied B-Raf from papillary thyroid cancer material. The remaining 40% were found to be B-Raf negative. B-Raf positivity was detected in 10% of the patients whose renal cell carcinoma material B-Raf was studied. The remaining 90% were found to be B-Raf negative. Papillary thyroid cancer cases with B-Raf positivity were more advanced than those with negative B-Raf positivity. The extrathyroidal extension was statistically more advanced in patients with papillary thyroid cancer with B-Raf positivity. 1 case died during follow-up. The thyroid material of this case was B-raf positive and the survival was the shortest with 63 months.
Açıklama
Tıpta Uzmanlık
Anahtar Kelimeler
İç Hastalıkları, Internal diseases
